Daniel Catenacci, MD | Authors


Determining the Optimal Timing for Immunotherapy in Patients With GEJ Cancers

November 01, 2019

Daniel Catenacci, MD, discusses how he makes decisions with immunotherapeutic agents for the treatment of patients with gastroesophageal junction cancer. He says he bases his sequencing decisions on a number of factors.